Clinical Trial Update: A Study of Subcutaneous Versus Intravenous MabThera/Rituxan (Rituximab) in Combination With CHOP Chemotherapy in Patients With Previously Untreated CD20-Positive Diffuse Large B-Cell Lymphoma [Phase 3]

View source ↗

Summary

Phase 3 study comparing subcutaneous versus intravenous rituximab added to CHOP in previously untreated CD20-positive diffuse large B-cell lymphoma; results wer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Rituximab (MabThera / Rituxan) (rituximab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Lymphoma, Large B-Cell, Diffuse | Phase 3 | Status: COMPLETED | Results posted: 2016-02-12